USE OF AN ANTI-CD19 ANTIBODY TO TREAT MYASTHENIA GRAVIS

Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein. In particular, the disclosure provides for the use of Inebilizumab, a humanized, affinity-optimized, afucosylated IgG1 kappa monoclonal antibody to treat myasthenia gravis. L'Invention concerne des procédé...

Full description

Saved in:
Bibliographic Details
Main Authors RATCHFORD, JOHN N, KATZ, ELIEZER, ABUHSIRA, LIRON
Format Patent
LanguageEnglish
French
Published 10.11.2022
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein. In particular, the disclosure provides for the use of Inebilizumab, a humanized, affinity-optimized, afucosylated IgG1 kappa monoclonal antibody to treat myasthenia gravis. L'Invention concerne des procédés d'utilisation d'un anticorps anti-CD19 pour traiter une maladie auto-immune. En particulier, l'invention concerne l'utilisation d'inébilizumab, un anticorps monoclonal kappa IgG1 afucosylé, optimisé par affinité, humanisé pour traiter la myasthénie grave.
Bibliography:Application Number: CA20223217586